NASDAQ:ARIA - Ariad Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.99 0.00 (0.00 %)
(As of 05/25/2018 01:12 AM ET)
Previous Close$23.99
Today's Range$23.99 - $23.99
52-Week Range$4.67 - $23.99
VolumeN/A
Average Volume15.70 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Receive ARIA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:ARIA
CUSIP04033A10
Phone+1-617-4940400

Debt

Debt-to-Equity Ratio-11.28
Current Ratio3.17
Quick Ratio3.15

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-60.47%
Return on EquityN/A
Return on Assets-17.16%

Miscellaneous

Employees459
Outstanding Shares194,390,000

Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions

What is Ariad Pharmaceuticals' stock symbol?

Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."

How were Ariad Pharmaceuticals' earnings last quarter?

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) issued its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.70. The pharmaceutical company had revenue of $65.30 million for the quarter, compared to the consensus estimate of $60.64 million. Ariad Pharmaceuticals's revenue was up 133.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.28) earnings per share. View Ariad Pharmaceuticals' Earnings History.

Has Ariad Pharmaceuticals been receiving favorable news coverage?

News stories about ARIA stock have trended positive on Friday, Accern reports. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a news impact score of 0.42 on Accern's scale. They also gave media headlines about the pharmaceutical company an impact score of 45.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Ariad Pharmaceuticals?

Shares of ARIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ariad Pharmaceuticals' stock price today?

One share of ARIA stock can currently be purchased for approximately $23.99.

How can I contact Ariad Pharmaceuticals?

Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400.


MarketBeat Community Rating for Ariad Pharmaceuticals (ARIA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  451 (Vote Outperform)
Underperform Votes:  339 (Vote Underperform)
Total Votes:  790
MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ariad Pharmaceuticals (NASDAQ:ARIA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AHold
Consensus Rating Score: N/AN/AN/A2.29
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$20.60
Price Target Upside: N/AN/AN/A13.01% downside

Ariad Pharmaceuticals (NASDAQ:ARIA) Consensus Price Target History

Price Target History for Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals (NASDAQ:ARIA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2017SunTrust BanksDowngradeBuy ➝ Hold$24.00N/AView Rating Details
1/10/2017CowenReiterated RatingBuy$16.00N/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform ➝ Market PerformN/AView Rating Details
1/10/2017BarclaysUpgradeUnderweight ➝ Equal Weight$9.00 ➝ $24.00N/AView Rating Details
1/10/2017Jefferies GroupDowngradeBuy ➝ Hold$11.00 ➝ $24.00N/AView Rating Details
12/10/2016William BlairReiterated RatingOutperform$15.00N/AView Rating Details
12/1/2016JMP SecuritiesReiterated RatingMarket PerformN/AView Rating Details
11/3/2016Deutsche BankInitiated CoverageHold$9.50N/AView Rating Details
10/24/2016JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$9.97 ➝ $7.00N/AView Rating Details
6/20/2016Royal Bank of CanadaReiterated RatingHoldN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Ariad Pharmaceuticals (NASDAQ:ARIA) Earnings History and Estimates Chart

Earnings by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals (NASDAQ ARIA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q316($0.19)($0.14)$42.93 million$34.30 millionViewListenView Earnings Details
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.12)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314($0.30)($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.27)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.12)($0.18)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.02)$1.35ViewN/AView Earnings Details
5/10/2010Q1 2010($0.17)($0.21)ViewN/AView Earnings Details
3/16/2010Q4 2009($0.17)($0.17)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.18)($0.21)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.25)($0.24)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.26)($0.26)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.28)($0.24)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.30)($0.29)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.26)($0.25)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.22)($0.25)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.23)($0.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ariad Pharmaceuticals (NASDAQ:ARIA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ariad Pharmaceuticals (NASDAQ ARIA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 86.97%
Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Institutional Ownership by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals (NASDAQ ARIA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2017Daniel M BollagVPSell32,000$23.78$760,960.00161,404View SEC Filing  
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28197,884View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64129,404View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00226,272View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00208,772View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37288,141View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92228,772View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00273,208View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46248,208View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.6029,262View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72264,742View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50141,631View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25128,088View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96288,741View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.9061,099View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00318,203View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33294,803View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72316,212View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25264,490View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99325,784View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25150,586View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50139,242View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.0097,039View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99345,463View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75160,713View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68154,674View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16369,302View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27305,326View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06123,117View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.0961,099View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00240,449View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00122,224View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00334,086View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56104,917View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00280,481View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00107,613View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00148,063View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00104,296View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.5088,174View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00403,028View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00144,463View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00227,042View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63394,377View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00221,398View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.0091,157View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.5074,274View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00380,319View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.061,242,759View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ariad Pharmaceuticals (NASDAQ ARIA) News Headlines

Source:
DateHeadline
Leukemia Therapeutics Market is Determined to Cross US$ 12 Billion By 2022Leukemia Therapeutics Market is Determined to Cross US$ 12 Billion By 2022
www.marketwatch.com - May 17 at 5:18 PM
After $62 Billion Shire Win, Takeda CEO Faces More HeadachesAfter $62 Billion Shire Win, Takeda CEO Faces More Headaches
www.msn.com - May 9 at 9:08 AM
Takeda to buy Shire for $62 billionTakeda to buy Shire for $62 billion
www.bizjournals.com - May 8 at 9:02 AM
Shire (SHPG) Agrees to Be Acquired by Takeda for $62BShire (SHPG) Agrees to Be Acquired by Takeda for $62B
www.streetinsider.com - May 8 at 9:02 AM
Japans Takeda clinches $62 billion deal to buy drugmaker ShireJapan's Takeda clinches $62 billion deal to buy drugmaker Shire
www.reuters.com - May 8 at 9:02 AM
Takeda Moves to Join Pharma Giants With $62 Billion Shire DealTakeda Moves to Join Pharma Giants With $62 Billion Shire Deal
www.msn.com - May 8 at 9:02 AM
Takeda to buy Shire for $62B, creating state’s largest drugmakerTakeda to buy Shire for $62B, creating state’s largest drugmaker
www.bizjournals.com - May 8 at 9:02 AM
Cambridge’s Ironwood Pharmaceuticals to split into two businessesCambridge’s Ironwood Pharmaceuticals to split into two businesses
www.bizjournals.com - May 1 at 9:07 AM
Takeda is closing in on buying Adderall maker Shire for $64 billion in pharmas biggest deal of the yearTakeda is closing in on buying Adderall maker Shire for $64 billion in pharma's biggest deal of the year
www.businessinsider.com - April 25 at 9:06 AM
Shire accepts a $64b takeover offer from Takeda, will seek shareholders’ backingShire accepts a $64b takeover offer from Takeda, will seek shareholders’ backing
www.msn.com - April 25 at 9:06 AM
Shire bid marks Takedas latest - and biggest - push for global statusShire bid marks Takeda's latest - and biggest - push for global status
www.reuters.com - April 25 at 9:06 AM
Clarus Appoints Former Ariad CEO Paris Panayiotopoulos as Operating Partner and Member of its Investment TeamClarus Appoints Former Ariad CEO Paris Panayiotopoulos as Operating Partner and Member of its Investment Team
www.prnewswire.com - April 23 at 8:51 AM
Takeda sweetens bid for drug rival ShireTakeda sweetens bid for drug rival Shire
www.marketwatch.com - April 20 at 4:46 PM
Bidding war looms over Shire after £42.4bn Takeda offer rejectedBidding war looms over Shire after £42.4bn Takeda offer rejected
www.ft.com - April 19 at 4:56 PM
Shire Rejects Takedas $60 Billion Bid as Talks ContinueShire Rejects Takeda's $60 Billion Bid as Talks Continue
www.bloomberg.com - April 19 at 9:02 AM
Shire rejects £42.4bn takeover bid from TakedaShire rejects £42.4bn takeover bid from Takeda
www.ft.com - April 19 at 9:02 AM
Tim Clackson, Ph.D., Named to FORMA Therapeutics Board of DirectorsTim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors
www.bizjournals.com - April 9 at 9:15 AM
Shire Would Be a Big Pill for Takeda to SwallowShire Would Be a Big Pill for Takeda to Swallow
www.wsj.com - March 30 at 4:51 PM
Takeda shares fall on possible Shire bidTakeda shares fall on possible Shire bid
www.marketwatch.com - March 29 at 9:24 AM
Takeover whispers about Shire growing much louderTakeover whispers about Shire growing much louder
www.msn.com - March 29 at 9:24 AM
Shares in £33 billion pharma giant Shire jump 25% after a possible takeover approach was announcedShares in £33 billion pharma giant Shire jump 25% after a possible takeover approach was announced
www.businessinsider.com - March 28 at 4:44 PM
Japanese pharma group Takeda weighs bid for ShireJapanese pharma group Takeda weighs bid for Shire
www.ft.com - March 28 at 4:44 PM
Takeda eyes bid for Shire to make $90B drug giantTakeda eyes bid for Shire to make $90B drug giant
www.marketwatch.com - March 28 at 4:44 PM
Ariad Pharmaceuticals (ARIA) and Cascadian Therapeutics (CASC) Financial ComparisonAriad Pharmaceuticals (ARIA) and Cascadian Therapeutics (CASC) Financial Comparison
www.americanbankingnews.com - March 24 at 3:24 PM
BioCanCell Announces Two New Key Hires in Clinical Development ... - GlobeNewswire (press release)BioCanCell Announces Two New Key Hires in Clinical Development ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 5:38 PM
Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors - GlobeNewswire (press release)Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - March 7 at 5:38 PM
Why Innoviva Inc. Stock Jumped TuesdayWhy Innoviva Inc. Stock Jumped Tuesday
www.fool.com - February 13 at 4:12 PM
Sarissa Capital Reconstitutes Innoviva Board Of DirectorsSarissa Capital Reconstitutes Innoviva Board Of Directors
finance.yahoo.com - February 13 at 4:12 PM
Wired News – Bristol-Myers Squibb’s Phase-3 CheckMate-227 Study Met its Co-Primary EndpointWired News – Bristol-Myers Squibb’s Phase-3 CheckMate-227 Study Met its Co-Primary Endpoint
finance.yahoo.com - February 7 at 9:30 AM
Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice PresidentUltragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President
finance.yahoo.com - January 29 at 9:35 AM
Contrasting Ariad Pharmaceuticals (ARIA) & Its PeersContrasting Ariad Pharmaceuticals (ARIA) & Its Peers
www.americanbankingnews.com - January 15 at 5:08 PM
Critical Contrast: Ariad Pharmaceuticals (ARIA) vs. Its CompetitorsCritical Contrast: Ariad Pharmaceuticals (ARIA) vs. Its Competitors
www.americanbankingnews.com - January 11 at 9:32 AM
What to watch during health-care investings biggest week of the yearWhat to watch during health-care investing's biggest week of the year
finance.yahoo.com - January 8 at 11:05 AM
Analyzing Ariad Pharmaceuticals (ARIA) and Its RivalsAnalyzing Ariad Pharmaceuticals (ARIA) and Its Rivals
www.americanbankingnews.com - January 4 at 5:12 AM
Critical Survey: Xenetic Biosciences (XBIO) versus Ariad Pharmaceuticals (ARIA)Critical Survey: Xenetic Biosciences (XBIO) versus Ariad Pharmaceuticals (ARIA)
www.americanbankingnews.com - January 2 at 3:16 PM
Financial Survey: Ariad Pharmaceuticals (ARIA) versus Its CompetitorsFinancial Survey: Ariad Pharmaceuticals (ARIA) versus Its Competitors
www.americanbankingnews.com - December 24 at 9:38 AM
US cancer drugmaker Ignyta in advanced sale talks - NasdaqUS cancer drugmaker Ignyta in advanced sale talks - Nasdaq
www.nasdaq.com - December 23 at 3:45 PM
Head to Head Review: Ariad Pharmaceuticals (ARIA) vs. Its CompetitorsHead to Head Review: Ariad Pharmaceuticals (ARIA) vs. Its Competitors
www.americanbankingnews.com - December 23 at 1:24 AM
Exclusive: U.S. cancer drugmaker Ignyta in advanced sale talks ... - ReutersExclusive: U.S. cancer drugmaker Ignyta in advanced sale talks ... - Reuters
www.reuters.com - December 22 at 7:28 AM
Contrasting Ariad Pharmaceuticals (ARIA) & Sucampo Pharmaceuticals (SCMP)Contrasting Ariad Pharmaceuticals (ARIA) & Sucampo Pharmaceuticals (SCMP)
www.americanbankingnews.com - December 18 at 3:28 AM
Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17
finance.yahoo.com - December 15 at 3:24 PM
Ariad Pharmaceuticals settles investor lawsuit for $3.5 million - ReutersAriad Pharmaceuticals settles investor lawsuit for $3.5 million - Reuters
www.reuters.com - December 1 at 3:24 PM
Ariad Pharmaceuticals settles investor lawsuit for $3.5 millionAriad Pharmaceuticals settles investor lawsuit for $3.5 million
www.reuters.com - December 1 at 8:13 AM
Head to Head Survey: Ariad Pharmaceuticals (ARIA) & Heat Biologics (HTBX)Head to Head Survey: Ariad Pharmaceuticals (ARIA) & Heat Biologics (HTBX)
www.americanbankingnews.com - November 27 at 5:22 PM
Takeda Chief Seeks to Forge Identity Beyond Japan With DealsTakeda Chief Seeks to Forge Identity Beyond Japan With Deals
www.bloomberg.com - November 16 at 9:21 PM
Pulse Biosciences Announces Transition of Board of Directors, Extends Appreciation to Retiring Members and ... - Business Wire (press release)Pulse Biosciences Announces Transition of Board of Directors, Extends Appreciation to Retiring Members and ... - Business Wire (press release)
www.businesswire.com - November 3 at 9:20 AM
Incyte Reports 2017 Third-Quarter Financial Results And Updates On Key Clinical ProgramsIncyte Reports 2017 Third-Quarter Financial Results And Updates On Key Clinical Programs
www.thestreet.com - November 1 at 3:27 AM
Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs - Business Wire (press release)Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs - Business Wire (press release)
www.businesswire.com - October 31 at 5:18 PM
Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical OperationsBlueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations
www.bizjournals.com - October 10 at 5:24 PM
​Shire officially inks sublease for former Ariad site in Cambridge - Boston Business Journal​Shire officially inks sublease for former Ariad site in Cambridge - Boston Business Journal
www.bizjournals.com - October 5 at 6:50 PM

SEC Filings

Ariad Pharmaceuticals (NASDAQ:ARIA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ariad Pharmaceuticals (NASDAQ:ARIA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ariad Pharmaceuticals (NASDAQ ARIA) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.